Cargando…

Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review

INTRODUCTION: Individualizing glycemic targets to goals of care and time to benefit in persons with type 2 diabetes is good practice, particularly in populations at risk of hypoglycemia and adverse outcomes relating to the use of antihyperglycemics. Guidelines acknowledge the need for relaxed target...

Descripción completa

Detalles Bibliográficos
Autores principales: Black, Cody D., Thompson, Wade, Welch, Vivian, McCarthy, Lisa, Rojas-Fernandez, Carlos, Lochnan, Heather, Shamji, Salima, Upshur, Ross, Farrell, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306119/
https://www.ncbi.nlm.nih.gov/pubmed/27981503
http://dx.doi.org/10.1007/s13300-016-0220-9
_version_ 1782507133264199680
author Black, Cody D.
Thompson, Wade
Welch, Vivian
McCarthy, Lisa
Rojas-Fernandez, Carlos
Lochnan, Heather
Shamji, Salima
Upshur, Ross
Farrell, Barbara
author_facet Black, Cody D.
Thompson, Wade
Welch, Vivian
McCarthy, Lisa
Rojas-Fernandez, Carlos
Lochnan, Heather
Shamji, Salima
Upshur, Ross
Farrell, Barbara
author_sort Black, Cody D.
collection PubMed
description INTRODUCTION: Individualizing glycemic targets to goals of care and time to benefit in persons with type 2 diabetes is good practice, particularly in populations at risk of hypoglycemia and adverse outcomes relating to the use of antihyperglycemics. Guidelines acknowledge the need for relaxed targets in frail older adults, but there is little guidance on how to safely deprescribe (i.e. stop, reduce or substitute) antihyperglycemics. METHODS: The purpose of this study was to synthesize evidence from all studies evaluating the effects of deprescribing versus continuing antihyperglycemics in older adults with type 2 diabetes. To this end, we searched MEDLINE, EMBASE, and Cochrane Library (July 2015) for controlled studies evaluating the effects of deprescribing antihyperglycemics in adults with type 2 diabetes. All such studies were eligible for inclusion in our study, and two independent reviewers screened titles, abstracts and full-text articles, extracted data, and evaluated risk of bias. Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment and a narrative summary were completed. RESULTS: We identified two controlled before-and-after studies, both of very low quality. One study found that an educational intervention decreased glyburide use while not compromising glucose control. The other reported that cessation of antihyperglycemics in elderly nursing home patients resulted in a non-significant increase in glycated hemoglobin (HbA1C). No significant change in hypoglycemia rate was found in the only study with this outcome measure. CONCLUSIONS: There is limited evidence available regarding deprescribing antihyperglycemic medications. Adequately powered, high-quality studies, particularly in the elderly and with clinically important outcomes, are required to support evidence-based decision-making. PROTOCOL REGISTRATION NUMBER: CRD42015017748. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-016-0220-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5306119
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-53061192017-02-27 Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review Black, Cody D. Thompson, Wade Welch, Vivian McCarthy, Lisa Rojas-Fernandez, Carlos Lochnan, Heather Shamji, Salima Upshur, Ross Farrell, Barbara Diabetes Ther Review INTRODUCTION: Individualizing glycemic targets to goals of care and time to benefit in persons with type 2 diabetes is good practice, particularly in populations at risk of hypoglycemia and adverse outcomes relating to the use of antihyperglycemics. Guidelines acknowledge the need for relaxed targets in frail older adults, but there is little guidance on how to safely deprescribe (i.e. stop, reduce or substitute) antihyperglycemics. METHODS: The purpose of this study was to synthesize evidence from all studies evaluating the effects of deprescribing versus continuing antihyperglycemics in older adults with type 2 diabetes. To this end, we searched MEDLINE, EMBASE, and Cochrane Library (July 2015) for controlled studies evaluating the effects of deprescribing antihyperglycemics in adults with type 2 diabetes. All such studies were eligible for inclusion in our study, and two independent reviewers screened titles, abstracts and full-text articles, extracted data, and evaluated risk of bias. Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment and a narrative summary were completed. RESULTS: We identified two controlled before-and-after studies, both of very low quality. One study found that an educational intervention decreased glyburide use while not compromising glucose control. The other reported that cessation of antihyperglycemics in elderly nursing home patients resulted in a non-significant increase in glycated hemoglobin (HbA1C). No significant change in hypoglycemia rate was found in the only study with this outcome measure. CONCLUSIONS: There is limited evidence available regarding deprescribing antihyperglycemic medications. Adequately powered, high-quality studies, particularly in the elderly and with clinically important outcomes, are required to support evidence-based decision-making. PROTOCOL REGISTRATION NUMBER: CRD42015017748. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-016-0220-9) contains supplementary material, which is available to authorized users. Springer Healthcare 2016-12-15 2017-02 /pmc/articles/PMC5306119/ /pubmed/27981503 http://dx.doi.org/10.1007/s13300-016-0220-9 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Black, Cody D.
Thompson, Wade
Welch, Vivian
McCarthy, Lisa
Rojas-Fernandez, Carlos
Lochnan, Heather
Shamji, Salima
Upshur, Ross
Farrell, Barbara
Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review
title Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review
title_full Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review
title_fullStr Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review
title_full_unstemmed Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review
title_short Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review
title_sort lack of evidence to guide deprescribing of antihyperglycemics: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306119/
https://www.ncbi.nlm.nih.gov/pubmed/27981503
http://dx.doi.org/10.1007/s13300-016-0220-9
work_keys_str_mv AT blackcodyd lackofevidencetoguidedeprescribingofantihyperglycemicsasystematicreview
AT thompsonwade lackofevidencetoguidedeprescribingofantihyperglycemicsasystematicreview
AT welchvivian lackofevidencetoguidedeprescribingofantihyperglycemicsasystematicreview
AT mccarthylisa lackofevidencetoguidedeprescribingofantihyperglycemicsasystematicreview
AT rojasfernandezcarlos lackofevidencetoguidedeprescribingofantihyperglycemicsasystematicreview
AT lochnanheather lackofevidencetoguidedeprescribingofantihyperglycemicsasystematicreview
AT shamjisalima lackofevidencetoguidedeprescribingofantihyperglycemicsasystematicreview
AT upshurross lackofevidencetoguidedeprescribingofantihyperglycemicsasystematicreview
AT farrellbarbara lackofevidencetoguidedeprescribingofantihyperglycemicsasystematicreview